Role of short-term use of L. acidophilus DDS-1 and B. lactis UABLA-12 in acute respiratory infections in children: a randomized controlled trial.
Dr. Alan Gaby, MD
Author: Gerasimov SV, et al
Reference: Role of short-term use of L. acidophilus DDS-1 and B. lactis UABLA-12 in acute respiratory infections in children: a randomized controlled trial. Eur J Clin Nutr 2016;70:463-469.
Design: Randomized, double-blind, placebo-controlled trial.
Participants: Three hundred fifteen children (aged 3-12 years) who had a household member with symptoms of an acute respiratory infection (ARI).
Study Medication and Dosage: A daily probiotic or placebo, beginning on the day the household member became ill and continuing for 10 days. The probiotic preparation contained Lactobacillus acidophilus DDS-1 (NCIMB 30333) and Bifidobacterium lactis UABLA-12 (NCIMB 30334) in a proportion of 1:4, at a dose of 5 billion colony-forming units per day, with 50 mg of fructooligosaccharides.
Primary Outcome Measures: Incidence, duration, and severity of ARIs.
Key Findings: The proportion of children who developed an ARI was nonsignificantly lower by 12% (57% vs. 65%; p = 0.26), the median duration of illness was significantly lower by 29% (5.0 vs. 7.0 days; p < 0.001) and the median severity of ARIs was significantly lower by 54% (p < 0.001) in the probiotic group than in the placebo group.
Practice Implications: In this study, supplementation of children with a probiotic preparation at the first sign of illness of a household member nonsignificantly decreased the incidence and significantly decreased the duration and severity of secondary acute respiratory infections. Probiotic organisms may help eradicate or prevent the growth of pathogenic organisms by competing with them for nutrients and colonization sites, by producing antimicrobial compounds, and by enhancing the immune function of the host. The results of this study are consistent with other research showing that various probiotics can prevent infections.